AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%

Compare Watch

ABOT

HOLD

Abbott Laboratories Pakistan

Pharmaceuticals · 1.16% of the KSE-100

Price

Rs 4.35

Market cap

Rs 4.3bn

12-month return

-26.4%

Rank

41 of 101

55composite

Rule-based42

ML ranker79

Conviction70

Why the engine ranks it here

Abbott Laboratories Pakistan (ABOT) screens as fairly valued against the rest of the KSE-100, ranking 41 of 101 on a composite score of 55/100.

Abbott Laboratories Pakistan sits in the Pharmaceuticals sector and scores best on valuation (49/100), weakest on growth (30/100). At PKR 4.35 the shares trade on a P/E of 0.4x, 0.04x book, a 60.0% dividend yield. The Piotroski F-Score is 7 of 9 (strong) and the Altman Z''-Score is 6.63 (financially sound).

What it does well

ABOT backs its reported profit with 1.27x of operating cash.

Profitability & earnings quality

ABOT reports conservative accruals at -1.1% of assets.

Profitability & earnings quality

ABOT trades at 0.04x book value, below peers.

Valuation

What holds it back

ABOT keeps only 3.0% of every rupee of sales as profit.

Profitability & earnings quality

ABOT runs a thin 5.8% operating margin.

Profitability & earnings quality

ABOT free cash flow yield is -150.0%.

Valuation

What would change this view

→ two consecutive quarters of revenue growth above the sector median

Five-pillar breakdown

Each pillar scores the company against sector peers, where 50 is the sector average.

Profitability & earnings quality30% weight45

Valuation25% weight49

Balance-sheet strength20% weight37

Growth15% weight30

Price trend10% weight45

The classic screens

Piotroski tests nine accounting facts about improvement; Altman scores the distance from financial distress.

Piotroski F-Score

7 / 9

strong · 7 of 9 tests passed

Altman Z''-Score

6.63

safe zone · safe above 5.85

Profitable on assets

ROA 4.1%

Cash generative

CFO PKR 15,143m

Returns improving

ROA 4.1% vs 3.7% a year ago

Earnings backed by cash

CFO PKR 15,143m vs profit PKR 11,916m

Deleveraging

debt/assets 0.20 vs 0.23

Liquidity improving

current ratio 1.84 vs 1.78

Margin expanding

gross margin 22.3% vs 24.8%

Assets working harder

asset turnover 1.38x vs 1.42x

No shareholder dilution

990m shares vs 990m

Altman components

Working capital / assets0.201

Retained earnings / assets0.298

Operating profit / assets0.077

Equity / liabilities0.548

Sales / assets1.328

Price history

Weekly closes. Beta 0.47 against the index, annualised volatility 37%, RSI 69.

+20.8% over this window

Reported accounts

The last twelve quarters as filed, in PKR millions. The publication date is what the engine uses to decide when a figure became knowable.

Quarter	Revenue	Gross profit	Operating	Net income	EPS	Filed
2025 Q4	Rs 100.9bn	Rs 34.9bn	Rs 10.9bn	Rs 6.7bn	6.75	2026-04-30
2025 Q3	Rs 104.3bn	Rs 24.5bn	Rs 6.6bn	Rs 3.6bn	3.63	2025-11-14
2025 Q2	Rs 109.4bn	Rs 26.8bn	Rs 7.3bn	Rs 4.2bn	4.25	2025-08-14
2025 Q1	Rs 97.7bn	Rs 25.6bn	Rs 7.2bn	Rs 3.9bn	3.99	2025-05-15
2024 Q4	Rs 90.7bn	Rs 12.6bn	Rs 2.2bn	Rs 164m	0.17	2025-04-30
2024 Q3	Rs 95.2bn	Rs 25.9bn	Rs 7.5bn	Rs 3.4bn	3.47	2024-11-14
2024 Q2	Rs 103.5bn	Rs 26.2bn	Rs 7.3bn	Rs 3.0bn	3.04	2024-08-14
2024 Q1	Rs 99.2bn	Rs 23.4bn	Rs 6.3bn	Rs 2.1bn	2.16	2024-05-15
2023 Q4	Rs 91.6bn	Rs 21.1bn	Rs 5.6bn	Rs 1.5bn	1.53	2024-04-29
2023 Q3	Rs 98.4bn	Rs 22.6bn	Rs 6.0bn	Rs 1.7bn	1.67	2023-11-14
2023 Q2	Rs 101.9bn	Rs 22.7bn	Rs 5.9bn	Rs 1.5bn	1.56	2023-08-14
2023 Q1	Rs 93.4bn	Rs 20.1bn	Rs 5.1bn	Rs 1.2bn	1.16	2023-05-15

Ranked against Pharmaceuticals

Every peer in the same sector, ordered by composite score. These are the companies whose ratios set this one's z-scores.

FEROZFerozsons Laboratories2.1x61

ABOTAbbott Laboratories Pakistan0.4x55

AGPAGP Limited0.4x50

HINOONHighnoon Laboratories0.5x50

GLAXOGlaxoSmithKline Pakistan0.5x48

SEARLThe Searle Company0.5x46

Scored as of 31 December 2025. Generated by an automated screen for research and educational use. Not investment advice, and not a substitute for a SECP-licensed adviser.